Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Context: Annual iv administration of 5 mg zoledronate decreases fracture risk. The skeletal effects of annual treatment with doses of zoledronate under 4 mg have not been assessed. Objective: Our objective was to determine the skeletal effects of single doses of zoledronate of 5 mg or less. Design, Setting, and Participants: This was a double-blind, randomized, placebo-controlled trial over 1 yr at an academic research center in 180 postmenopausal women with osteopenia. Intervention: Intervention was a single baseline administration of iv zoledronate in doses of 1, 2.5, or 5 mg, or placebo. Main Outcome Measures: The primary endpoint was change in bone mineral density (BMD) at the lumbar spine. Secondary endpoints were change in BMD at the proximal femur and total body and changes in biochemical markers of bone turnover. Results: After 12 months, change in spine BMD was greater in each of the zoledronate groups than in the placebo group [mean (95% confidence interval) difference vs. placebo was 3.5% (2.2–4.8%) for 1 mg, 4.0% (2.7–5.3%) for 2.5 mg, and 3.6% (2.3–4.9%) for 5 mg zoledronate, P < 0.001 for each dose]. Change in BMD at the total hip was greater in each of the zoledronate groups than the placebo group [mean (95% confidence interval) difference vs. placebo was 2.7% (1.9–3.5%) for 1 mg, 3.6% (2.8–4.4%) for 2.5 mg, and 3.6% (2.8–4.4%) for 5 mg zoledronate, P < 0.001 for each dose]. Each of the bone turnover markers, β-C-terminal telopeptide of type I collagen and procollagen type I N-terminal propeptide, was lower by at least 40% in each of the zoledronate groups than the placebo group throughout the trial (P < 0.001 vs. placebo for each marker for each dose). There was evidence for a dose-dependent effect of zoledronate on each of the markers (P for trend <0.001). Conclusion: Annual administration of doses of iv zoledronate lower than 5 mg produces substantial antiresorptive effects. Trials assessing the antifracture efficacy of low doses of zoledronate are justified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Self-citationOnce-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986 · cited 5×
“J Clin Endocrinol Metab, January 2012, 97(1):286–292 jcem.”
BackgroundInfluentialSelf-citationPiaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428
Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa074941 · Cited by 2,003 · cited 1×
“When administered as an annual 5-mg iv infusion, the bisphosphonate zoledronate decreases the risk of fractures in osteoporotic populations by 35–70%, depending upon the skeletal site (1, 2), and decreases mortality by 28% after hip fracture (2).”
BackgroundDenosumab in postmenopausal women with low bone mineral density.
McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228
Reporting of Noninferiority and Equivalence Randomized Trials: An Extension of the CONSORT Statement
Piaggio, G., Elbourne, D. R., Altman, D. G., Pocock, S. J., Evans, S. J. W., & CONSORT Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.10.1152 · Cited by 1,153
Research works printed but not linked: 20
- Grey, 2009, The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women., J Clin Endocrinol Metab, 94, 538, 10.1210/jc.2008-2241 · DOI · Paper page
- Grey, 2010, Prolonged anti-resorptive activity of zoledronate: a randomized controlled trial., J Bone Miner Res, 25, 2251, 10.1002/jbmr.103 · DOI
- McClung, 2009, Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial., Obstet Gynecol, 114, 999, 10.1097/AOG.0b013e3181bdce0a · DOI · Paper page
- Reid, 2002, Intravenous zoledronic acid in postmenopausal women with low bone mineral density., N Engl J Med, 346, 653, 10.1056/NEJMoa011807 · DOI · Paper page
- Reid, 2010, Characterization of and risk factors for the acute-phase response after zoledronic acid., J Clin Endocrinol Metab, 95, 4380, 10.1210/jc.2010-0597 · DOI · Paper page
- Brown, 2002, The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis., Calcif Tissue Int, 71, 103, 10.1007/s00223-002-2011-8 · DOI · Paper page
- Schnitzer, 2000, Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group., Aging (Milano), 12, 1
- Watson, 2006, Health spending rising faster than GDP in most rich countries., BMJ, 333, 60, 10.1136/bmj.333.7558.60-a · doi:10.1136/bmj.333.7558.60-a
- Odvina, 2005, Severely suppressed bone turnover: a potential complication of alendronate therapy., J Clin Endocrinol Metab, 90, 1294, 10.1210/jc.2004-0952 · DOI · Paper page
- Lenart, 2008, Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate., N Engl J Med, 358, 1304, 10.1056/NEJMc0707493 · DOI · Paper page
- Kwek, 2008, An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy., Injury, 39, 224, 10.1016/j.injury.2007.08.036 · DOI · Paper page
- Shane, 2006, Osteonecrosis of the jaw: more research needed., J Bone Miner Res, 21, 1503, 10.1359/jbmr.060712 · DOI
- Heckbert, 2008, Use of alendronate and risk of incident atrial fibrillation in women., Arch Intern Med, 168, 826, 10.1001/archinte.168.8.826 · DOI · Paper page
- Black, 1996, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group., Lancet, 348, 1535, 10.1016/S0140-6736(96)07088-2 · DOI · Paper page
- Liberman, 1995, Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. [see comment]., N Engl J Med, 333, 1437, 10.1056/NEJM199511303332201 · DOI · Paper page
- Sebba, 2004, Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis., Curr Med Res Opin, 20, 2031, 10.1185/030079904X16768 · DOI
- Orwoll, 2010, Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study., J Bone Miner Res, 25, 2239, 10.1002/jbmr.119 · DOI · Paper page
- Rosen, 2010, Placebo-controlled trials in osteoporosis: proceeding with caution., N Engl J Med, 363, 1365, 10.1056/NEJMsb1002227 · doi:10.1056/nejmsb1002227
- Luckey, 2003, Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis., Obstet Gynecol, 101, 711
- Glover, 2009, Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States., J Bone Miner Res, 24, 389, 10.1359/jbmr.080703 · DOI · Paper page
Cited by
Calcium intake and bone mineral density: systematic review and meta-analysis
Tai, V., Leung, W., Grey, A., Reid, I. R., & Bolland, M. J. (2015) · BMJ · doi:10.1136/bmj.h4183 · Cited by 408
Self-citationSystematic review and statistical analysis of the integrity of 33 randomized controlled trials
Bolland, M. J., Avenell, A., Gamble, G. D., & Grey, A. (2016) · Neurology · doi:10.1212/wnl.0000000000003387 · Cited by 106
Self-citationBolland, M. J., Gamble, G. D., Avenell, A., & Grey, A. (2019) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2019.03.001 · Cited by 31
“We pooled anonymised individual patient data from 1 3 single-centre, placebo-controlled RCTs [11-23] carried out by our group, as previousl y described [6].”
BackgroundMethodSelf-citationBolland, M. J., Gamble, G. D., Avenell, A., Grey, A., & Lumley, T. (2019) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2019.05.006 · Cited by 27
Self-citation
Metadata
- Authors
- Grey, A., Bolland, M., Wong, S., Horne, A., Gamble, G., & Reid, I. R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-01-01
- Volume
- 97
- Issue
- 1
- Pages
- 286-292
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2036909315
- Cited by
- 51
- References
- 7
- FWCI
- 3.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial. https://app.cochat.ai/papers/10.1210/jc.2011-2081
- The paper
- Grey, A., Bolland, M., Wong, S., Horne, A., Gamble, G., & Reid, I. R. (2012). Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2011-2081
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.